TWA
CSTL icon

TCI Wealth Advisors’s Castle Biosciences CSTL Stock Holding History

TCI Wealth Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-164
Closed -$3.73K – 672
2023
Q1 		$3.73K Buy
+164
New +$4.01K ﹤0.01% 1730
2022
Q2 		– Sell
-171
Closed -$8K – 2317
2022
Q1 		$8K Buy
171
+26
+18% +$1.07K ﹤0.01% 1234
2021
Q4 		$6K Buy
145
+67
+86% +$3.5K ﹤0.01% 1511
2021
Q3 		$5K Sell
78
-23
-23% -$1.62K ﹤0.01% 1563
2021
Q2 		$7K Buy
101
+50
+98% +$3.3K ﹤0.01% 1192
2021
Q1 		$3K Buy
51
+30
+143% +$2.25K ﹤0.01% 1504
2020
Q4 		$1K Hold
21
– – ﹤0.01% 1354
2020
Q3 		$1K Hold
21
– – ﹤0.01% 1299
2020
Q2 		$1K Hold
21
– – ﹤0.01% 1230
2020
Q1 		$1K Hold
21
– – ﹤0.01% 1217
2019
Q4 		$1K Buy
+21
New +$513 ﹤0.01% 1313

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's CSTL Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 164 shares — an estimated $3.73K sold.

TCI Wealth Advisors first reported a position in CSTL in Q4 2019 and held it in 11 quarters. The position peaked at $8K in Q1 2022. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 164 Castle Biosciences shares in Q2 2023, an estimated $3.73K.
  • TCI Wealth Advisors first reported a position in Castle Biosciences in Q4 2019 and held it in 11 quarters.
  • TCI Wealth Advisors's Castle Biosciences position peaked at $8K in Q1 2022.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.